Verve Therapeutics, Inc. has paused enrollment in its Phase Ib Heart-1 trial of gene-edited cholesterol medicine VERVE-101 after a patient experienced liver enzyme elevations and low platelet counts. But while the company has decided to prioritize its development of a different asset with the same target, VERVE-102, it said VERVE-101 still might have a shot.
The biotech company said on 2 April that it had voluntarily paused enrollment in the study in heterozygous familial hypercholesterolemia (HeFH) after a sixth patient on the 0.45mg/kg dose experienced asymptomatic grade 3 ALT elevation and thrombocytopenia
Key Takeaways
-
Verve paused enrollment in its Phase Ib study of gene-editing candidate VERVE-101 after a sixth patient experienced grade 3 ALT elevations and thrombocytopenia.
-
The company plans to focus more on VERVE-102, which has the same target but uses a different lipid nanoparticle technology
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?